Cost analysis of in-centre nocturnal compared with conventional hemodialysis

Ben Wong1,4, Mark Courtney1, Robert P Pauly1, Kailash Jindal1 and Scott Klarenbach1,2,3*

Abstract

Background: Provision of in-centre nocturnal hemodialysis (ICNHD; 6–8 hours thrice weekly) is associated with health benefits, but the economic implications of providing this treatment are unclear.

Objective: We conducted a health care costing study comparing ICNHD to in-centre thrice-weekly conventional hemodialysis (CvHD).

Design: Micro-costing of both ICNHD and CvHD as practiced at our centre.

Setting: Hemodialysis unit at a tertiary-care hospital in Edmonton.

Participants: An informal survey of 2 other Canadian ICNHD programs was conducted to inform practices that may deviate from ours to guide sensitivity analysis.

Measurements: Resources consumed for each strategy were determined, and the cost of each unit (CAN $2012) was used to calculate incremental costs of ICNHD and CvHD.

Methods: We focused on resources that differ between strategies (staffing, dialysis materials, and utilities). The reference case considered 1:3 staff to patient ratio; alternate scenarios explored nursing pay grade and ratio, full care vs. self-care dialysis (including training costs), and medication costs.

Results: In the reference case, ICNHD was $61 more costly per dialysis treatment compared with CvHD ($9,538 per patient per year). Incremental annual costs for staffing, dialysis materials, and utilities were $8,201, $1,193, and $144, respectively. If ICNHD reduces medication use (anti-hypertensives, bone mineral metabolism medications), the incremental cost of ICNHD decreases to $8,620 per patient per year. In a scenario of self-care ICNHD utilizing a staff-to-patient ratio of 1:10, ICNHD is more costly in year 1 ($15,196), but results in cost savings of $2,625 in subsequent years compared with CvHD.

Limitations: The findings of this cost analysis may not be generalizable to other health care systems, including other parts of Canada.

Conclusions: Compared to CvHD, provision of ICNHD is more expensive, largely driven by increased staffing costs as patients dialyze longer. Alternate staffing models, including self-care ICNHD with minimal staff, may lead to net cost savings. The incremental cost of treatment should be considered in the context of impact on patient health outcomes, staffing model, and pragmatic factors, such as current capacity for daytime CvHD and the capital costs of new dialysis stations.

Keywords: Health care costs, Economic analysis, Hemodialysis, In-centre nocturnal hemodialysis

* Correspondence: swk@ualberta.ca
1Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
2Institute of Health Economics, Edmonton, Alberta, Canada
Full list of author information is available at the end of the article

© 2014 Wong et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

The cost of caring for patients with end-stage renal disease (ESRD) is considerable, largely driven by the provision of chronic dialysis [1]. The majority of ESRD patients are either not suitable for a kidney transplant, or must wait an increasing number of years on dialysis until renal transplantation given the scarcity of available organs. While strategies to increase peritoneal dialysis have been implemented in many jurisdictions, hemodialysis (HD) remains the most common modality, with the majority of those (~80%) receiving conventional thrice-weekly intermittent HD in a satellite or in-centre dialysis unit [2].

There is interest in offering nocturnal HD to patients due to its purported benefits of improved fluid volume and blood pressure control, regression of left ventricular hypertrophy, improved phosphate control, and increased quality of life [3-7]. However, some patients are thought to be unsuitable candidates for a variety of reasons, including inappropriate home environment, lack of social support, inadequate personal resources, or comorbidity precluding self-administration of HD (e.g. severe visual impairment, debilitating arthritis, stroke, etc.). In one centre, ~16% of HD patients were deemed to be appropriate candidates for home nocturnal HD (HNHD) [8]. As such, renal programs are considering in-centre nocturnal HD (ICNHD), typically conducted overnight in an existing in-centre dialysis unit for 6–8 hours thrice weekly. In addition to potential improvements in patient health outcomes and to facilitate patient lifestyle preferences, dialysis providers...
may also consider ICNHD as a strategy to increase in-centre patient treatment capacity without further expansion of existing HD stations.

Several economic analyses have demonstrated that home HD is either cost neutral or affords cost savings compared to in-centre conventional HD (CvHD), predominantly due to savings associated with nursing care [9-11]; no study has examined ICNHD. To inform rational use of ICNHD, we sought to determine the incremental costs of ICNHD compared with CvHD from a health care perspective.

Study context
Program description
The Northern Alberta Renal Program (NARP) oversees and manages renal care in the northern Alberta, Canada with a catchment of approximately 1.7 million. In a pilot program, 12 patients receive ICNHD (6 per HD shift on alternate nights) in an outpatient HD unit at a tertiary-care hospital in Edmonton. This HD unit provides 3 daytime CvHD shifts (18 HD stations per shift, 4 hours per session) with staff-to-patient ratio of 1:3. ICNHD occurs from 2200 to 0600 and the 6 patients are cared for by 2 Registered Nurses (RNs) or 1 RN and 1 Licensed Practical Nurse (LPN). The patients dialyze in beds to facilitate sleep (chairs are removed), and space between stations is increased to allow room for the bed and reduce noise; dividers are also set up to enhance patient privacy. Patients are referred for ICNHD at the discretion of their attending nephrologist, and priority is given to patients with suboptimal ultrafiltration or clearance on CvHD, intra-dialytic hypotension, or lifestyle considerations, including employment or education that conflict with daytime in-centre CvHD; and these patients cannot perform home HD. The duration of ICNHD sessions ranges from 6 to 8 hours, depending on patient preference.

Methods
Micro-costing methods, comprised of identification, measurement, and valuation of resources, was conducted for ICNHD and CvHD [12]. Identification of relevant health care resources was conducted through iterative discussion with ICNHD nursing staff, NARP financial analyst, clinical engineering, and technical manager overseeing water treatment, focusing on resource use that differs between the two modalities. Identified health care resource categories include staffing, dialysis materials, and utilities (Additional file 1: Table S1). In the reference case, HD machine maintenance, patient-borne costs, and physician billing were equivalent. An informal survey of 2 other Canadian ICNHD programs was conducted to inform practices that may deviate from ours to guide sensitivity analysis.

Staffing costs accounted for salaries and benefits of RNs and LPNs. All other staffing costs, including the salaries of nephrologists, unit clerks, social workers, and other allied health professionals, were assumed equivalent between the two HD modalities. HD materials cost accounted for costs related to dialysis tubing, dialysis needle, dialyzer, dialysate, and bicarbonate solution. To reflect our ICNHD setup, we did not include the cost of setting up and dismantling the HD unit for the nocturnal shift. Depending on the HD unit, additional costs relating to minor renovations may need to be accounted for. Utility costs per treatment factored into costs relating to water and electricity consumption (Additional file 1: Table S1).

Staff (RNs and LPNs) cost per dialysis treatment were calculated on a per hour basis and distributed equally among the patients based on the staff-to-patient ratio for the respective dialysis modality. For materials cost, we tabulated the number of units of the various dialysis supplies consumed per HD session. As accurate water and electricity usage per machine per dialysis treatment for home CvHD and HNHD patients were available, this data was used to inform utility cost. Respective units of measurement for water and electricity consumption per HD session were captured in liters and kilowatt-hours.

The constituent costs were summed to arrive at total cost per HD session for both ICNHD and CvHD, and subsequently, calculated on a per-patient-year basis. All costs were expressed in 2012 Canadian dollars.

Scenario analyses were also conducted to reflect other practices in Canada. A scenario of self-care ICNHD (with both a 1:6 and a 1:10 staff-to-patient ratio) was assessed, where patients receive training during the initiation of ICNHD and then perform machine setup and takedown, as well as access cannulation, with either no or reduced nursing assistance. Training costs (inflated to CAN $2012), arising from 3.65 weeks of training, were obtained from a micro-costing study of patients enrolled a randomized-controlled trial (RCT) that compared HNHD and CvHD [11]. The additional cost of patient training, $17,821 per patient, which accounts for nursing time, capital costs, and equipment per patient, is added to the cost of providing ICNHD in the first year. A scenario exploring the effect of nursing grade mix (50% RNs vs. 100% RN) on incremental costs was also explored.

Difference in medication costs for ICNHD patients versus CvHD patients was examined. We used results from the Alberta RCT [11] (which used units of medications and formulary prices inflated to CAN $2012) to inform medication costs of anti-hypertensive agents, bone mineral metabolism medications, and erythropoietin-stimulating agents (ESAs) for those on CvHD. Medication costs for ICNHD patients were informed by the Alberta RCT (which showed cost reduction in anti-hypertensive
agents and bone mineral metabolism medications only) and other observational studies reporting on medication use in ICNHD vs. CvHD, which showed cost reduction in all 3 medication classes [13-18].

ICNHD may be considered as an alternate strategy to creating new dialysis units and attendant capital costs when existing patients cannot be accommodated. A scenario analysis was performed to explore possible incremental costs. We assumed a scenario in which there is a surplus of HD patients in the context of an existing HD unit functioning at full capacity. All patients would then either be accommodated by ICNHD, or be treated with CvHD in a newly built in-centre dialysis unit. We explored the effects of size (4, 6, 9 stations) and capacity (25%, 50%, 75%, 100%) of the new HD unit. Capital costs of establishing new HD units were based on estimates from NARP.

Results
In the reference case (1:3 staff-to-patient ratio with nursing grade of 50% RN), ICNHD was $61 more costly per dialysis treatment compared with CvHD (Table 1, Additional file 2: Table S2). Difference in staffing cost was responsible for greater than 85% of the incremental cost; materials and utility during ICNHD accounted for 13% and 2% respectively. Incremental annual costs per dialysis patient for staffing, dialysis materials, and utilities were $8,201, $1,193, and $144, respectively for ICNHD vs. CvHD. Overall, ICNHD was $9,538 more per patient-year (Table 1).

Accounting for plausible reduction in anti-hypertensive agents and bone mineral metabolism medications for ICNHD patients compared to CvHD patients, the cost differential between the two HD modalities is reduced from $9,538 to $8,620 per annum (Table 2). If we also account for reduction in ESA requirement (suggested in observational studies, but not shown in RCTs), the cost differential further reduces to $6,119 per annum.

Scenario analyses of alternate staff-to-patient ratio and nursing grade of 50% RN are presented in Figure 1. Incremental costs are similar with 100% RN (figure not shown). A self-care ICNHD program with a 1:10 staff-to-patient ratio and a nursing grade of 50% RN resulted in an annual incremental cost of $15,196 (vs. $9,538 in the reference case) in the patient’s first year of dialysis and annual saving of $2,625 in subsequent years (Figure 1).

Incremental costs of constructing a new HD unit vs. providing ICNHD is shown in Table 3. A new HD unit would be required to operate for close to 10 years at near-full capacity before the initial capital costs equilibrate with the increased operating costs of ICNHD (relative to CvHD). This was consistent across various sizes and capacities of the new HD unit.

Discussion
In this cost analysis of ICNHD, we have demonstrated that provision of ICNHD cost approximately $9500 more per annum per patient relative to CvHD. This is primarily attributed to increased staffing costs of RNs and LPNs from both longer duration of dialysis and increased wage rates for overnight shifts. An alternate scenario of self-care ICNHD that utilized a higher nursing staff-to-patient ratio substantially reduce the incremental cost, with some scenarios demonstrating cost savings after the first year with ICNHD.

Self-care ICNHD program with a higher nursing staff-to-patient ratio (1:6 and 1:10) offers an attractive alternative from a health payer perspective. This variation of ICNHD is already operational in other centres (Michael Copland, personal communication, March 28, 2013). Patients are trained the same way as for HNHD patients; they are expected to be competent with all aspects of HD care, except for machine maintenance. While ICNHD, compared to CvHD, can potentially lead to net cost savings, a concern exists in that it may detract from patients choosing HNHD, for which operating costs are likely lower and there is stronger evidence of clinical benefits [4,5]. Accordingly, providers should be encouraged to first consider HNHD and offer patients the opportunity to transfer to HNHD after they have completed their training for self-care ICNHD.

A pragmatic rationale for ICNHD is patient numbers exceeding existing in-centre HD unit capacity. While increasing the number of patients on home dialysis therapies may offset this to some degree, the majority of dialysis patients are likely to require in-centre HD. If the capacity of existing in-centre HD units were exceeded, either expanding an existing HD facility or

| Table 1 Absolute and incremental costs of ICNHD and CvHD |
|---------------------------------|-----------------|-----------------|------------------|
| Cost categories                | Absolute ICNHD cost ($) | Absolute CvHD cost ($) | Incremental cost ($) (ICNHD - CvHD) |
| 1. Materials per treatment     | 43.49            | 35.84            | + 7.65           |
| 2. Staff per treatment         | 111.38           | 58.81            | + 52.57          |
| 3. Utilities per treatment     | 2.73             | 1.81             | + 0.92           |
| Total cost per treatment       | 157.60           | 96.46            | + 61.14          |
| Total annual cost per patient  | 24,585.86        | 15,048.28        | + 9,537.58       |

ICNHD: in-centre nocturnal hemodialysis; CvHD: conventional hemodialysis.
constructing a new facility would be required. A previous study showed that the cost of renovating existing space for a six-station satellite unit is approximately $250,000 to $300,000 Canadian [19], while the cost of constructing a new HD facility consisting of 6 to 9 stations is estimated to be $2.5-3.5 million Canadian. Our scenario analysis shows that implementing ICNHD to maximize use of existing infrastructure may be advantageous given the very large capital costs of creating a new dialysis unit, despite the greater incremental treatment costs of ICNHD relative to CvHD. If the incremental treatment costs can be further reduced, as by employing a self-care ICNHD program, ICNHD becomes even more attractive. These estimates should be approached with caution, as the true capital cost of a new HD unit are not known with certainty, may vary by setting and jurisdiction, and may be modified if the unit is de novo or is utilizing currently unused space. Further, the decision to create new units is also influenced by other factors, including geographical considerations and anticipated future growth of the HD population.

ICNHD may be more attractive if other benefits are realized. Although the clinical benefits of ICNHD have not been rigorously evaluated, published literature suggests clinical improvements are achieved. ICNHD improves blood pressure and phosphate control, with concomitant reductions in requirements of anti-hypertensives and phosphate binders compared with CvHD [6,13-17,20-26]. Reduced need for ESAs to achieve similar levels of hemoglobin has also been found [13,15-17,21], although not in RCTs; we have accounted for savings from reduced ESA requirements for interest only as current evidence does not support a reduction in use. Some studies have also suggested reduced mortality and hospitalization rates for ICNHD patients compared to CvHD patients [14,17,18].

Table 2 Impact of difference in medication requirement on relative costs between ICNHD and CvHD

| Resource category                                    | CvHD ($) | ICNHD ($) | Δ Cost ($, ICNHD – CvHD) |
|------------------------------------------------------|----------|-----------|--------------------------|
| Medication                                           |          |           |                         |
| Anti-hypertensives                                   | 756.00   | 378.00    | (−378.00)                |
| ESAs                                                 | 6,252.00 | 3751.20   | (−2,500.80)              |
| Bone mineral metabolism medications                 | 1,080.00 | 540.00    | (−540.00)                |
| Reference – no difference in medication use (annual cost/patient) | 15,048.28 | 24,585.86 | +9,537.58                |
| Reduced anti-HTN and bone mineral metabolism medications only (annual cost/patient) | 16,884.28 | 25,503.86 | +8,619.58                |
| Reduced in all medication categories (annual cost/patient) | 23,136.28 | 29,255.06 | +6,118.78                |

Assumptions:
- 50% reduction in number of anti-hypertensives required based on observational studies [13-17].
- 40% reduction in required ESA dose based on observational studies [16-18].
-50% reduction in amount of bone mineral metabolism medications required based on observational studies [13,15,16,18].

ICNHD: in-centre nocturnal hemodialysis (7 hour sessions, 3x/week, 1:3 staff-to-patient ratio); CvHD conventional hemodialysis (4 hour sessions, 3x/week, 1:3 staff-to-patient ratio); ESAs: erythropoiesis-stimulating agents.

Figure 1 Scenario analyses of alternate staff-to-patient ratio with 50% RN and 50% LPN. Costs are incremental compared with CvHD.

ICNHD, in-centre nocturnal hemodialysis; CvHD, conventional hemodialysis; RN, registered nurse; LPN, licensed practical nurse.
Table 3 Estimated incremental costs comparing construction of new dialysis unit vs. ICNHD (ICNHD – CvHD)

| Size of new HD unit added | Capacity of added HD unit |
|---------------------------|---------------------------|
|                           | 25% | 50%  | 75%  | 100% |
| 4 stations (capital cost ~ $2,000,000) |      |      |      |      |
| 1 year                    | $1,942,775 | $1,885,549 | $1,828,324 | $1,771,098 |
| 5 years                   | $1,713,873 | $1,427,745 | $1,141,618 | $855,490  |
| 10 years                  | $1,427,745 | $855,490  | $283,236   | (−$289,019) |
| 6 stations (capital cost ~ $2,700,000) |      |      |      |      |
| 1 year                    | $2,614,162 | $2,528,324 | $2,442,485 | $2,356,647 |
| 5 years                   | $2,270,809 | $1,841,618 | $1,412,427 | $983,236  |
| 10 years                  | $1,841,618 | $983,236  | $124,853   | (−$733,529) |
| 9 stations (capital cost ~ $4,000,000) |      |      |      |      |
| 1 year                    | $3,866,474 | $3,742,485 | $3,608,959 | $3,484,971 |
| 5 years                   | $3,332,369 | $2,712,427 | $2,044,796 | $1,424,853 |
| 10 years                  | $2,664,739 | $1,424,853 | $89,592    | (−$1,150,293) |

Assumptions:
- all patients can be accommodated by ICNHD or would be treated with CvHD in a newly built in-centre dialysis unit of varying station capacity.
- annual operating cost per ICNHD patient $24586; annual operating cost per CvHD patient $15048 (incremental cost $ x annually).
- capital costs of establishing new HD units based on estimates from the Northern Alberta Renal Program.
- capacity refers to the use of stations within the unit, assuming 3 shifts per day, 6 days per week.

ICNHD: in-centre nocturnal hemodialysis; CvHD: conventional hemodialysis.

However, the clinical benefits associated with ICNHD do not necessarily imply causation. To-date, there has been no RCTs evaluating the benefits of ICNHD relative to other HD modalities; most studies are either cohort studies or before-after studies that are subject to the limitations with respect to internal validity. As such, we have used potential cost savings in scenario analyses, and have not conducted a comprehensive economic evaluation that considers health consequences, including cardiovascular events, and survival.

There have been few studies evaluating the quality of life of ICNHD patients [13,22,25,27]. This precludes the feasibility of conducting cost utility studies in this area at present. However, there are potential productivity gains afforded by ICNHD. ICNHD allows patients to maintain full-time employment that would otherwise not be possible with CvHD; it may also allow patients to receive training for independent home HD in conjunction with their HD treatments overnight, while maintaining employment in the day. Future studies in ICNHD should include quality of life measures and assessment of the effect on patients’ employment.

Our study has important strengths. Many economic evaluations have previously been performed on various forms of intensive HD therapy, but to our knowledge, never with respect to ICNHD. Using a micro-costing technique, we have formally identified the incremental costs of ICNHD compared with CvHD. However, we also acknowledge several limitations with this study. First, cost comparisons between ICNHD and CvHD were assumed to be equivalent with regards to HD machine maintenance, patient-borne costs, overhead, and physician billing. Potential cost differential in these areas may be missed, but may not be important given that differences in staffing costs between the two HD modalities contributed to a large proportion of the overall cost differential. Second, in our scenario analysis, the cost of patient training for self-care ICNHD may be underestimated. The relatively short training period was informed by the Alberta RCT, where a large proportion of patients who were established on HNHD enrolled in this trial [4]. The average duration of training may be higher in reality; in NARP, new home HD patients typically require 6 weeks of training. However, the training cost accounted for a dedicated RN performing patient training/teaching (in addition to another nursing staff caring for the patient on dialysis), thus potentially overestimating the staffing component of training costs; our estimate of overall training costs may be a reasonable approximation. Third, our estimates of the relative reduction in medication requirements for ICNHD patients were based on findings from a few cohort and quasi-experimental studies [13-18]. The precise effect would require more rigorous investigations, but we used conservative estimates in our analysis. Finally, the findings of this cost analysis may not be generalizable to other health care systems, including other parts of Canada. Differences in physician billings, salary structures of RNs and LPNs, and construction costs of new HD units may result in findings different than those identified here.

Conclusions
In conclusion, we found that, compared to CvHD, provision of ICNHD is more costly, largely driven by increased staffing costs related to longer patient dialysis time. Alternate
staffing models, including self care ICNHD, results in net cost savings. The cost of treatment should be considered in the context of impact on patient outcomes, staffing model, and other factors, such as current available capacity for in-centre HD.

Additional files

Additional file 1: Table S1. Components of the Differential Cost Between ICNHD and CoHID, Unit of Measurement, Valuation Method, and Valuation Sources.

Additional file 2: Table S2. Constituent Differential Costs of ICNHD and CoHID.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

All authors were involved in the conception and design of this study. BW and SK were responsible for data acquisition, and BW conducted analyses. BW drafted the manuscript, and all authors performed critical revision. All authors read and approved the final manuscript.

Acknowledgements

SK is supported by career salary awards from the Alberta Heritage Foundation for Medical Research/Alberta Innovates Health Solutions. SK, MC, RP are supported by a joint initiative between Alberta Health and Wellness and the University of Alberta.

Author details

1. Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. 2. Institute of Health Economics, Edmonton, Alberta, Canada. 3. Alberta Kidney Disease Network, Edmonton, Alberta, Canada. 4. Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.

Received: 14 April 2014 Accepted: 5 June 2014 Published: 2 July 2014

References

1. Manns BJ, Mendelsohn DC, Taub KJ. The economics of end-stage renal disease care in canada: Incentives and impact on delivery of care. Int J Health Care Finance Econ 2007, 7(2–3):149–169.
2. Canadian institute for health information. Canadian organ replacement registry annual report: treatment of end-stage organ failure in canada. 2011. Available at: https://secure.cihi.ca/free_products/2011_CORR_Annual_Report_final_e.pdf. Assessed 02/02/2014.
3. Pieratos A, Ouwendyk M, Francoeur R, Vas S, Raj DS, Eccleston AM, Langos V, Udlall R. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol 1998, 9(5):859–868.
4. Culleton BF, Walsh M, Klaerenbach SW, Morris G, Scott-Douglas N, Quinn RR, Tonelli M, Donnelly S, Friedrich MG, Kumar A, Mahalati H, Hemmelgarn BR, Manns BJ. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007, 298(11):1291–1299.
5. Rocco MV, Lockridge RS Jr, Beck GJ, Eggers PW, Gassman JJ, Greene T, Larive B, Chan CT, Chertow GM, Copland M, Hoy CD, Lindsay RM, Levin NW, Orr PB, Pieratos A, Pinkin MJ, Rajagopalan S, Stokes BJ, Unruh ML, Star RA, Kliger AS. Frequent Hemodialysis Network (FHN) Trial Group, Kliger A, Eggers P, Briggs J, Hostetter T, Nava A, Star R, Augustine B, Mohr P, et al. The effects of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007, 298(11):1291–1299.
6. Weinrich T, De Ios Rios T, Gajty A, Passakk-Duerto J. Effects of an increase in time vs frequency on cardiovascular parameters in chronic hemodialysis patients. Clin Nephrol 2006, 66(4):433–439.
7. Nesrallah GE, Lindsay RM, Cuerden MS, Garg AX, Port F, Austin PC, Moise LM, Pieratos A, Chan CT, Zimmerman D, Lockridge RS, Courchoud C, Chazot C, Offshorn N, Levin A, Copland M, Courtney M, Steele A, McFarlane PA, Geary DF, Pauly RP, Komenda P, Suri RS. Intensive hemodialysis associates with improved survival compared with conventional hemodialysis. J Am Soc Nephrol 2012, 23(4):696–705.
8. McFarlane PA, Pierrots A, Redelmeier DA. Cost savings of home nocturnal versus conventional in-center hemodialysis. Kidney Int 2002, 62(6):2216–2222.
9. McFarlane PA. Reducing hemodialysis costs: conventional and quotidian home hemodialysis in canada. Semin Dial 2004, 17(2):118–124.
10. McFarlane PA, Bayoumi AM, Pierrots A, Redelmeier DA. The impact of home nocturnal hemodialysis on end-stage renal disease therapies: a decision analysis. Kidney Int 2006, 69(8):798–805.
11. Klaerenbach S, Tonelli M, Pauly R, Walsh M, Culleton B, Lee H, Hemmelgarn B, Manns B. Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial. J Am Soc Nephrol 2014, 25(3):587–594.
12. Gold MR, Siegel JE, Russell LB, Weinsein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
13. Bujeja A, Dacouris N, Thomas A, Mantorena R, McFarlane P, Donnelly S, Goldstein M. In-center nocturnal hemodialysis: another option in the management of chronic kidney disease. Clin J Am Soc Nephrol 2009, 4(4):778–783.
14. Cravedi P, Ruggenenti P, Mingardi G, Sghirlanzoni MC, Remuzzi G. Thrice-weekly in-center nocturnal hemodialysis: an effective strategy to optimize chronic dialysis therapy. Int J Artif Organs 2009, 32(1):12–19.
15. Demirici MS, Celik G, Ozkahya M, Tumuklu M, Toz H, Asci G, Duman S, Rasci A, Kirceli F, Odogan O, Demirici C, Can I, Isik IO, Ok E. Long Dialysis Group. Effects of thrice weekly nocturnal hemodialysis on arterial stiffness. Atherosclerosis 2012, 220(2):477–485.
16. Ok E, Duman S, Asci G, Tumuklu M, Oren Tertzko O, Kayikcioglu M, Toz H, Adam SM, Yilmaz M, Tonbul HZ, Ozkahya M, Long Dialysis Study Group. Comparison of 4- and 8-h dialysis sessions in thrice-weekly in-center haemodialysis: a prospective, case-controlled study. Nephrol Dial Transplant 2011, 26(4):1287–1296.
17. David S, Kumpers P, Eisenbach GM, Haller H, Kielstein JT. Prospective evaluation of an in-center conversion from conventional haemodialysis to an intensified nocturnal strategy. Nephrol Dial Transplant 2009, 24(7):2232–2240.
18. Jin X, Rong S, Mei C, Ye C, Chen J, Chen X. Effects of in-center nocturnal versus conventional hemodialysis on endothelial dysfunction. Ther Apher Dial 2012, 16(4):334–340.
19. Soroka SD, Kibera BD, Jacobs P. The marginal cost of satellite versus in-center hemodialysis. Hemodial Int 2005, 9(2):196–201.
20. Aliotti S, Molino A, Maris M, Bonfanti G, Pelli V. Long nocturnal dialysis. Blood Purif 2002, 20(6):525–530.
21. Jin X, Rong S, Mei C, Ye C, Chen J, Chen X. Effects of thrice-weekly in-center nocturnal vs. conventional hemodialysis on integrated backscatter of myocardial tissue. Hemodial Int 2011, 15(2):200–210.
22. Lacson E Jr, Yang W, Lester K, Offshorn N, Lazarus JM, Hakim RM. Outcomes associated with in-center nocturnal hemodialysis from a large multicenter program. Clin J Am Soc Nephrol 2010, 5(2):220–226.
23. Lacson E Jr, Xu J, Suri RS, Nesrallah G, Lindsay R, Garg AX, Lester K, Offshorn N, Lazarus M, Hakim RM. Survival with three-times weekly in-center nocturnal versus conventional hemodialysis. J Am Soc Nephrol 2012, 23(6):687–695.
24. Fajardo L, Campistrous N, Rios T, Gomez T. Evaluation of serum phosphate in long intermittent hemodialysis. Kidney Int Suppl 2003, 85:566–568.
25. Troidle L, Hotchkiss M, Finkelstein F. A thrice weekly in-center nocturnal hemodialysis program. Adv Chronic Kidney Dis 2007, 14(3):244–248.
26. Wald R, Yan AT, Perl J, Jiang D, Donnelly MS, Leong-Poi H, McFarlane PA, Weinstein JJ, Goldstein MB. Regression of left ventricular mass following conversion from conventional hemodialysis to thrice weekly nocturnal hemodialysis. BMC Nephrol 2012, 13:8. 2369:13–3.
27. Doss S, Schiller B. Dialysis overnight: in-center nocturnal hemodialysis programs showing growth. Nephrol News Issues 2011, 25(8):22. 24, 26.